Research Article | | Peer-Reviewed

Impact of Mutations in the D-loop Region in Ovarian Cancer in Senegalese Women

Received: 15 October 2024     Accepted: 12 November 2024     Published: 29 November 2024
Views:       Downloads:
Abstract

In Senegal, ovarian cancer is the 3rd most common cancer in women with an incidence of 5.0/100,000 women. Thirty-five cancerous tissues, twenty-seven healthy tissues were included in this study. Due to the anatomical position of the ovary, the removal of a sample of suspicious tissue from each patient involves surgery through laparotomy or laparoscopy after obtaining consent. DNA extraction, polymerase chain reaction (PCR) and sequencing were performed to obtain sequences. BioEdit version 7.0.5.3 2005, Harlequin version 3.0, DnaSP version 5.10.01, MEGA 6 were used to perform the analyses. The results show a higher percentage of transition in cancerous tissues (91.45) than in healthy tissues (75.19) in contrast to transversions which are greater in healthy tissues (24.84) than in cancerous tissues (8.54), and the mutation rate (R) is also higher in cancerous tissues (10.712) than in healthy tissues (3.079). Analysis of the polymorphism revealed high values of haplotypic diversity in both cancerous tissues (0.662±0.085) and healthy tissues (0.997±0.011), and low nucleotide diversity values in both tissues (cancerous tissues=0.00922±0.00175; healthy tissues=0.01539±0.00175), these results show us that the genetic evolution of mutations in ovarian cancer has a strong polymorphism. It was also found that the value of the genetic distance between healthy tissues (0.016) was higher than that observed between cancerous tissues (0.009). The genetic distance between healthy and cancerous tissues is 0.015 closer than that observed between healthy tissues. The value of genetic differentiation between healthy and cancerous tissues is significant; this demonstrates a much faster proliferation of cancer cells. The objective of this study is, on the one hand, to better understand the target population by clearly identifying demographic parameters and on the other hand, to evaluate the involvement of somatic mutations and mitochondrial DNA gene expression in the occurrence of ovarian cancer in women in Senegal. The specific objectives are to search for mutations of interest by sequencing mtDNA genes with quasi-maternal inheritance and the impact of these mutations in the D-loop region in healthy and diseased tissues in the patient, but also to learn about the diversity, differentiation and genetic evolution of ovarian cancer in Senegalese women.

Published in International Journal of Genetics and Genomics (Volume 12, Issue 4)
DOI 10.11648/j.ijgg.20241204.18
Page(s) 127-135
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Cancer, Ovary, Mutations, Epidemiology, D-loop, Senegal

1. Introduction
A generic term applied to a large group of diseases that can affect any part of the body with an uncontrolled proliferation of abnormal cells, cancer is the second leading cause of death in the world with 8.8 million deaths in 2015 and nearly one in 6 deaths worldwide is due to cancer according to the WHO. About 70% of cancer deaths occur in low- and middle-income countries, and its economic impact is significant and growing. According to the WHO, the total annual cost of cancer to the economy has been estimated at about $1160 billion. It has become a real public health problem and has become a field of research that is becoming increasingly popular.
The global annual incidence and mortality were estimated at 313,959 and 207,252 respectively. As the ovary is a very deep organ, the disease is generally only detected at an advanced stage of malignancy (stage III or stage IV / according to the FIGO classification) and the 5-year survival rarely exceeds 40% despite treatments. In Senegal, ovarian cancer is the 3rd most common cancer in women with an incidence of 5.0/100,000 women.
The family history of ovarian cancer is the main risk factor, through the transmission of susceptibility genes. This is because 10% of ovarian cancer patients inherited a genetic mutation that may have caused . Mutations that occur in cells destined to become eggs are passed on from one parent to their offspring. Indeed, genomic instability is a phenomenon recognized as central to oncogenesis . This also applies to the stability of the mitochondrial genome, which has its own replication and repair machinery .
Mitochondria are essential organelles that have their own genome, mitochondrial DNA (mtDNA), present in hundreds or even thousands of copies per cell. Regulating the abundance of this genome is an important issue for the cell, whose dysfunctions are responsible for hereditary and common pathologies, including cancer. The actors involved in mtDNA replication as well as nuclear factors involved in mtDNA biogenesis are known, but the regulators of mtDNA abundance remain unknown (the genes responsible for regulating or maintaining a normal number of mtDNA copies in cells). In fact, these mtDNA abnormalities are the cause of about 20% of mitochondrial diseases.
Subsequently, we will try to evaluate the impact of mutations in the D-loop region in healthy and cancerous individuals through certain parameters such as: genetic diversity indices, genetic distance at the intra- and inter-tissue level, degrees of differentiation (Fst), and analysis of mismatch distribution curves.
2. Materials Et Methods
2.1. Study Population
This study was conducted in patients recruited from the Joliot Curie Institute at Aristide Le Dantec University Hospital. Patients received in this department were referred by community health centres, district hospitals, central hospitals and private clinics in Senegal but also in neighbouring countries. A standardized form was used to collect this information,(demographic characteristics and medical and family history). Regarding the family study, we identified five Senegalese families, each with at least 2 sick individuals. Informed consent was obtained for each of the affected individuals as well as the non-affected individuals who agreed to participate in the study. Due to the anatomical position of the ovary, the removal of a suspicious tissue sample requires surgery. This can be performed, depending on the case, by laparotomy (the patient's belly is open) or by laparoscopy (only small incisions are made in the patient's abdomen).
2.2. DNA Extraction, Polymerase Chain Reaction and Sequencing
First, the Qiagen DNeasy Tissue kit method was used for tissue DNA extractions. Then, we used the Puregene method (Puregene Commercial Kit from the company Gentra) where the samples are incubated at 55°C overnight with 100 μl of Cell Lysis solution and 20 μl of proteinase K. For each sample, the quality of the extracted genomic DNA was verified by electrophoretic migration on agarose gel in a 0.5X buffer (Tris-Base 2M, Acetic acid 1M, EDTA 0.05M) and a solution of Ethidium Bromide (BET: DNA intercalating agent). The gels are then placed under UV and the genomic DNA visualized by fluorescence. DNA size is approximated using a SmartLadder 200 base pair (bp) size marker. The polymerase chain reaction (PCR) is a molecular biology method that rapidly obtains, in vitro, a large number of identical DNA segments from an initial sequence. The PCR is an enzymatic amplification technique that makes to obtain a large number of identical copies of a DNA fragment. PCR required a reaction volume of 50 μL containing 32.9 μL of milliQ water, 5 μL of 10X buffer, 2 μL of dNTP, 2.5 μL for each primer (H408 and L16340), 0.1 μL of Taq polymerase, and 2 μL of cDNA. Briefly, the total DNA was subjected to the following PCR protocol: initial DNA denaturation at 95°C for 15 min, followed by 35 cycles at 95°C for 30 s, 62°C for 30 s, 72°C for 2 min, and final extension to 72°C for 10 min. Positive PCR products were purified and sequenced (See Table 1).
Table 1. Compositions of the PCR reaction mixture.

Amplified gene

Composants

Volume

D-loop

MilliQ water

32,9 μl

Tampon 10X

5 μl

dNTP

2 μl

MgCl2

3 μl

Primers (sense and nonsense)

5 μl

Polymerase Taq

0,1 μl

DNA extract

2 μl

The D-loop region was amplified by PCR from tissue extracts Table 2. PCR products are controlled by electrophoretic migration on 1.5% agarose gel from 5 μl of amplifia and 3 μl of bromophenol blue. The size of the amplified gene is estimated using a SmartLadder 200bp size marker. After UV visualization, the PCR products for which the primers have snagged, are frozen in 1.5 mL Eppendorf tubes for sequencing purposes. Sequencing is the technique of determining the nucleotide sequence of a DNA fragment. It was performed by an American company based in South Korea from 30 μL of PCR products and 15 μL of primer at 10 μΜ for each sample.
Table 2. Primer sequence and amplification condition for the PCR reactions.

Gene

Primer sequence

Amplification conditions

D-loop

H408 (5’TGTTAAAAGTGCATACCGCCA3’) L16340 (5’AGCCATTTACCGTACATAGCACA3’)

95°C for 15mn; 35 cycles (95°C for 30s, 62°C for 30s, 72°C for 2mn) 72°C for 10mn

2.3. Molecular Analysis
Sequences were verified, aligned and corrected by BioEdit software version 7.0.5.3 2005 which use using the Clusta W algorithm version 1.4 . A comparison of healthy and cancerous tissue sequences was made with the revised Cambridge reference sequence (NC_012920) in the MITOMAP database for the detection of potential D-Loop variants in ovarian cancer. For our genetic analyses which follow, two groups were formed: healthy tissue and cancerous tissue. The genetic diversity will be determined using DnaSP software version 5.10.01 and MEGA 6 software . The proportion of nucleotide differences per site and the average number of synonymous and non-synonymous substitutions per site using the model, as well as the nature of the mutations, were performed using MEGA 6 software . The number of polymorphic sites and the number of informative sites will also be determined by DnaSP version 5.10.01 . FSTs and their associated probabilities were calculated using Arlequin version 3.0 . A significant P value (P˂0.05) meant that there was genetic differentiation, and a non-significant P value (P>0.05) meant that there was no genetic differentiation. The genetic structure of the populations was apprehended by a hierarchical analysis, analysis of molecular variance (AMOVA). Neutrality tests such as the D of Tajima , the D* and F* of Fu and Li, the Fs of Fu was used to test the deviation of the neutrality hypothesis using the Arlequin software version 3.0 and with DnaSP version 5.10.01 .
3. Results
A total of 62 sequences with a length of 559 base pairs were obtained after alignment.
Mutations D-Loop
Table 3. D-Loop variations in ovary cancer.

Variation

Nature

TS

TC

locus

Associated diseases

C33G

Transversion

1

ATT

C61T

Transition

2

HVS2/ATT

C64T

Transition

2

HVS2/ATT

A73G

Transition

25

35

HVS2/ATT

T89C

Transition

20

HVS2/ATT

A93G

Transition

3

24

HVS2/ATT

A95C

Transversion

2

2

HVS2/ATT

G97A

Transition

20

HVS2/ATT

C114G

Transversion

1

HVS2/OH/ATT

G143A

Transition

3

HVS2/OH/ATT

T146C

Transition

6

26

HVS2/OH/ATT

Absence of endometriosis

C150T

Transition

10

30

HVS2/OH/ATT

Conflicting reports longevity/cervical carcinoma/risk of HPV infection

C151T

Transition

3

1

HVS2/OH/ATT

C151G

Transversion

1

HVS2/OH/ATT

T152C

Transition

15

33

HVS2/OH/ATT

C182T

Transition

7

31

HVS2/OH/ATT

G185T

Transversion

3

2

HVS2/OH/ATT

G185C

Transversion

2

HVS2/OH/ATT

C186A

Transversion

1

1

HVS2/OH/ATT

A189C

Transversion

1

1

HVS2/OH/ATT

A189G

Transition

1

HVS2/OH/ATT

T195C

Transition

14

32

HVS2/OH/ATT

Melanoma/MB-associated points

A197C

Transversion

1

HVS2/OH/ATT

C198T

Transition

6

30

HVS2/OH/ATT

T204C

Transition

4

6

HVS2/OH/ATT

T204G

Transversion

1

HVS2/OH/ATT

G207A

Transition

4

2

HVS2/OH/ATT

G221C

Transversion

1

HVS2/OH/ATT

Variation

Nature

TS

TC

Locus

Associated diseases

A232C

Transversion

1

HVS2/OH/ATT

A240T

Transversion

1

HVS2/OH/ATT

G247A

Transition

3

3

HVS2/OH/ATT

C256T

Transition

1

HVS2/OH/ATT

A263G

Transition

27

35

HVS2/OH/ATT

T279C

Transition

1

HVS2/OH/ATT

T292A

Transversion

1

HVS2/OH/ATT

A297G

Transition

1

HVS2/OH/ATT

C309T

Transition

1

HVS2/OH/ATT

C315CC

Insertion

26

34

HVS2/OH/ATT

Melanoma patients

G316C

Transversion

1

1

HVS2/OH/ATT

G316GA

insertion

1

1

HVS2/OH/ATT

C325T

Transition

26

HVS2/OH/ATT

C332T

Transition

1

HVS2/OH/ATT

A357G

Transition

3

2

HVS2/OH/ATT

T16386A

Transversion

2

ATT

G16390A

Transition

7

28

ATT

POAG-association potential

C16395G

Transversion

1

ATT

C16411A

Transversion

1

ATT

A16421C

Transversion

1

ATT

T16422C

Transition

1

ATT

T16468G

Transversion

1

ATT

T16469G

Transversion

2

ATT

G16477A

Transition

1

ATT

C16478A

Transversion

3

ATT

T16479A

Transversion

1

ATT

C16501G

Transversion

1

ATT

C16511T

Transition

1

ATT

T16519C

Transition

19

27

ATT

T16522A

Transversion

1

ATT

A16525G

Transition

1

ATT

C16527T

Transition

2

ATT

We obtained 559 base pairs of the D-Loop through the 62 sequences studied, 35 of which were of cancerous origin and 27 of healthy tissue. The study in Table 3 concerning the variations of the D-Loop in ovarian cancer shows that there are 60 variants. They are made up of 96.7% substitutions (55% transition, 41.7% transversion) and 3.3% insertion. The majority of these variations (42/60) are present in the hypervariable HVS2 region, followed by the ATT region (18/60). There are also variations present only in healthy tissues (55% (33/60) (Exp: C33G-G143A-T279C-C16411A-C16527T), which could constitute a protective action against the ovarian tumor, as well as mutations present only in cancerous tissues and which are much less numerous at 6.67% (Exp: T89C-G97A-C325T-T16386A). It should be noted that a variant is only considered a mutation when it is present only in cancerous tissues.
3.1. Indices of Genetic Diversity
The analysis of the Table 4 shows relative values of nucleotide composition with a slight predominance of T and G (cancerous tissue=57.71; healthy tissue=57.66) compared to A and C (cancerous tissue=42.29; healthy tissue=42.34) in both cancerous and healthy tissues. The percentage of transition is higher in cancerous tissues (91.45) than in healthy tissues (75.19) in contrast to transversions which are greater in healthy tissues (24.84) than in cancerous tissues (8.54), and the mutation rate (R) is also higher in cancerous tissues (10.712) than in healthy tissues (3.079). Analysis of the polymorphism revealed high values of haplotypic diversity in both cancerous tissues (0.662±0.085) and healthy tissues (0.997±0.011), and low nucleotide diversity values in both tissues (cancerous tissues=0.00922±0.00175; healthy tissues=0.01539±0.00175). The mean number of nucleotide differences (K) is greater in cancerous tissues (42.581) than in healthy tissues (11,901).
Table 4. Parameters of genetic variability of the sequences of healthy and cancerous tissues of the D-Loop.

Parameters

Cancerous tissues

Healthy tissues

Number of sequences

35

27

Number of haplotypic

8

26

Number of sites

559

559

Number of monomorphic sites

536

509

Number of polymorphic sites

23

50

Number of sparing information sites

19

23

Nucleotidic frequence

A G T C 24.91 30.20 27.51 17.38

A G T C 24.87 30.20 27.46 17.47

% Transitions

91.45

75.19

% Transversions

8.54

24.84

Rate of Transitions/Transversions=R

10.712

3.079

Haplotypic diversity (HD±SD)

0.662±0.085

0.997±0.011

Nucleotide diversity (Pi±SD)

0.00922±0.00175

0.01539±0.00175

average number of nucleotide differences (K)

42.581

11.901

3.2. Differentiation and Genetic Structuring
The values of genetic distance at the intra- and inter-tissue level and the degree of genetic differentiation (Fst) between healthy and cancerous tissues are shown in the Table 5. The results show that the value of the genetic distance between healthy tissues (0.016) is higher than that observed between cancerous tissues (0.009). The genetic distance between healthy and cancerous tissue is 0.015. The value of genetic differentiation between healthy and cancerous tissues is highly significant.
Table 5. Genetic distance at the intra- and inter-tissue level and degrees of differentiation (Fst).

Tissues

Genetic distance intra

Genetic distance inter

Fst (P-value)

Cancerous

0.009±0.002

0.015±0.003

0.333 (P=0.000)

Healthy

0.016±0.003

3.3. Genetics Demo Tests
Analysis of the Table 6 shows negative and non-significant statistical values of Tajima's D for both tissues (healthy tissue=-1.278, p=0.081; cancerous tissue=-0.266, p=0.443). There were also negative and significant Fs of Fu values (-19.113, p=0.000), D* (-1.921; 0.10 > P > 0.05) and F* (-2.091; 0.10 > P > 0.05). In contrast, the H value is positive but non-significant (3.442, p = 0.326). In cancerous tissues, it can be seen that the values of Fs of Fu (2.590, p=0.856), D* (0.514 P >0.10) and F* (0.303 P >0.10) are positive and not significant, while for H (-9.400 p=0.337) it is also non-significant but positive.
Table 6. Genetics demo tests.

Parameters

Healthy Tissues

Cancerous Tissues

D of Tajima

-1,278

-0,266

P-value

0,081

0,443

Fs of Fu

-19,113

2,590

3.4. Mismatch Distribution Analysis
The mismatch distribution curves show a multimodal pattern for both cancerous and healthy tissue. The SSD and RI demographic indices are not significant.
Figure 1. Mismatch curve distribution of cancerous (A) and healthy (B) tissues of the D-Loop.
SSD = 0.0846; P-value = 0.16 SSD = 0.0027; P-value 0.88
Raggedness = 0.179; P-value =0.06 Raggedness = 0.004; P-value 0.99
4. Discussion
The aim of this study was to determine the impact of D-loop mutations on ovarian cancer progression. The D-loop is a non-coding system and regulatory region of the mitochondrial genome. MtDNA is the only genetic material in the human genome not contained in the nucleus. In recent years, somatic mutations in mtDNA have been increasingly studied in ovarian cancers and the D-loop region is considered a key location for mutations in human cancer . The control of the mtDNA region is highly polymorphic and contains the hypervariable zone HVS2 characterized by a high degree of polymorphism and most variations (42/60 or 70%). Variations in the D-Loop consist of 91.45% transition and 8.54% transversion in cancerous tissues, and 75.19% transition and 24.84% transversion in healthy tissues. This is in line with the assertion of , who showed in their study that the majority of mutations in cancer cells are transitions Variations such as C33G, G143A, T279C, C16411A, and C16527T, present only in healthy tissue, account for 55%, could have a protective action against ovarian tumors. However, the mutations such as T89C, G97A, C325T, and T16386A, present only in cancerous tissue, are much less numerous (6.67%). In our study, the A73G, A93G, C315CC, and T16519C variations identified at the D-loop in 23.33% of tumors have already been described by as polymorphic sites in the human population. Furthermore, according to , DNA polymorphism may act as a risk modifier in the late onset of diseases such as cancer. This raises the necessity of knowing whether polymorphism favors the development of mutations . Most somatic mtDNA mutations identified in human cancers (bladder, head and neck, lung, breast, ovary, and esophagus) are found in the hypervariable region of the promoter. Generally, it is concluded that the majority of the variants found are indeed somatically acquired . Considering that polymorphic D-loop sites have a neutral function, suggest that these somatic mutations could have functional consequences in cancer cells. Therefore, this also implies a possible impact of the genetic structure of D-Loop on the mode of mtDNA mutagenesis in human tumors. Some parameters (genetic diversity indices, genetic differentiation and structuring, demo-genetic tests, mismatch distribution analysis) such as the basic parameters of genetic diversity were also studied, showing variation in tumors. Indeed, tumor cells are generally characterized by faster cell proliferation, due to the presence of alterations in genes that regulate proliferation in normal cells . Mutations are the ultimate source of genetic variation that causes diversity in all organisms, thus playing the role of driving evolution . However, according to Moto Kimura's model known as the mutation and random drift theory, most genetic variability is neutral and polymorphisms are eliminated or fixed in individuals under the influence of the effects of genetic drift from the environment . The results of the D-loop genetic distance analysis show that the value of the genetic distance between healthy tissues (0.016) is higher than that observed between cancerous tissues (0.009), which could reflect the genetic difference that may exist between tissues. This finding is further confirmed by the significant genetic differentiation between healthy and cancerous tissues. Analysis of the polymorphism revealed high values of haplotypic diversity in both cancerous tissues (0.662±0.085) and healthy tissues (0.997±0.011), and low nucleotide diversity values in both tissues (cancerous tissues=0.00922±0.00175; healthy tissues=0.01539±0.00175), suggesting rapid development of cancer cells in ovarian tumors. These results follow the Darwinian model of cancer development formulated by according to which a neoplasia originates from a single cell that is the target of mutations that free it from the physiological mechanisms limiting its proliferation. Thus, a malignant tumor is a disease characterized by abnormally large cell proliferation inside a normal tissue of the body, thus threatening the survival of the latter. Tajima's D indices were negative and non-significant for both tissues (healthy tissue=-1.278 p=0.081; cancerous tissue=-0.266 p=0.443); whereas those of Fu Fs have negative and significant values (-19.113 p=0.000) in healthy tissues, and positive and non-significant values (2.590 p=0.856) in cancerous tissues. Therefore, in cancerous tissues, we observe non-significant values of Tajima D and Fu Fs, which allows us to affirm that the mutations found are neutral that is, they are not responsible for a disease . Indeed, for non-coding sequences such as mtDNA control region, a neutrality gap is likely explained by recent demographic changes rather than selection . Analysis of the mismatch distribution curves shows Nucleotide differences between haplotypes taken in pairs leading to a multimodal distribution. This is characteristic of an expanding population.
5. Conclusion
Ovarian cancer, which occurs in the female organs that produce eggs, is the deadliest neoplasia in women worldwide. It is a malignant tumor that affects one or both ovaries. It is a morphologically and biologically heterogeneous disease that has probably contributed to the difficulty of defining the molecular alterations associated with its development and progression. It is the second most common form of cancer in the female reproductive tract and the deadliest of the gynecologic malignancies. Our objective was to evaluate the diversity and genetic evolution of D-loop in ovarian cancer in Senegal. The results of the analyses showed a strong polymorphism in ovarian cancer and that the D-loop region is a highly mutagenic location. Some genetic diversity parameters have also shown variations in tumors that are the ultimate source of genetic variation. Our study also showed a slower proliferation due to a greater genetic distance between healthy tissues than in cancerous tissues. So the study of genetic diversity parameters revealed a variation in tumors. The results also showed a genetic difference between healthy and cancerous tissue.
Studies to identify the mutations that cause ovarian cancer will make a significant contribution to a better understanding of this disease in our population and to the discovery of effective solutions for appropriate and effective treatment and prevention. Further studies with a number of variables such as larger populations, ethnicity, grade and response to chemotherapy and involving the entire mtDNA genome would be needed to better elucidate the problem of ovarian cancer, its mutations, the disease process and the survival rate of patients.
Abbreviations

DNA

DeoxyriboNucleic Acid

WHO

World Health Organization

FIGO

International Federation of Gynecology and Obstetrics

HAH

High Authority of Health

mtDNA

Mitochondria DeoxyriboNucleic Acid

FST

Degree of Genetic Differentiation or Fixation Index

D-LOOP

Displacement Loop

PCR

Polymerase Chain Reaction

DNAsp

DeoxyriboNucleic Acid Sequence Polymorphism

MEGA

Molecular Evolutionary Genetics Analysis

AMOVA

Analysis of Molecular Variance

SSD

Sum of Squares Deviation

RI

Raggedness Index

HVS

Hypervariable Segments

Conflicts of Interest
The authors declare no conflicts of interest.
References
[1] Synthese_rapport_activite_2010
[2] Negrini S, Gorgoulis VG, Halazonetis TD. Instabilité génomique – une caractéristique évolutive du cancer. Nat Rev Mol Cell Biol. 2010; 11: 220–228.
[3] Vasileiou, PVS; Mourouzis, I.; Pantos, C. Principaux aspects concernant le maintien de l'intégrité du génome mitochondrial des mammifères. Int. J. Mol. Sci. 2017, 18, 1821.
[4] Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. InNucleic acids symposium series 1999 Jan 1 (Vol. 41, No. 41, pp. 95-98). [London]: Information Retrieval Ltd., c1979 c2000.
[5] Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Research. 1994 Nov 11; 22(22): 4673-80.
[6] RM Andrews, Je Kubacka, PF Chinnery, Les hiboux-lumière de la RN, DM Turnbull, N. Howell: Réanalyse et révision de la séquence de référence de Cambridge pour l'ADN mitochondrial humain. 1999 octobre; 23(2): 147.
[7] Rozas, J., Librado, P., Sánchez-Del Barrio, J. C., Messeguer, X. and Rozas, R. (2012) DnaSP Version 5 Help Contents [Help File].
[8] Tamura K, Stecher G, Peterson D, et al. MEGA6 Analyse génétique évolutive moléculaire Version 6.0. Mol Biol Evol. 2013. 30: 2725-2729.
[9] Nei M. & Gojobori T., (1986): Simple methods for estimating the numbers of synonymous & nonsynonymous nucleotide substitutions. Molecular Biology & Evolution (3): 418-426.
[10] B. Weir, WG Hill. Estimation des statistiques F. Publié dans la Revue annuelle de génétique 2002.
[11] Excoffier L, Estoup A, Cornuet J-M (2005) Bayesian Analysis of an Admixture Model With Mutations and Arbitrarily Linked Markers. Genetics 169: 1727-1738.
[12] Tajima, F. 1989a. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 123:585-595, 597-601.
[13] Fu, Y.-X. (1997) Statistical tests of neutrality of mutations against population growth, hitchhiking and backgroud selection. Genetics 147: 915-925.
[14] Guerra F, Kurelac I, Magini P, et al. Mitochondrial DNA genotyping reveals synchronous nature of simultaneously detected endometrial and ovarian cancers. Gynecol Oncol. 2011; 122(2): 457-458.
[15] Calloway CD, Reynolds RL, Herrin Jr GL, Anderson WW. The frequency of heteroplasmy in the HVII region of mtDNA differs across tissue types and increases with age. The American Journal of Genetics. 2000 Apr 1; 66(4): 1384-1397.
[16] Li H, Hong ZH. Mitochondrial DNA mutations in human tumor cells. Oncology Letters. 2012 Nov 1; 4(5): 868-872.
[17] Brandon M, Baldi PA, Wallace DC. Mitochondrial mutations in cancer. Oncogene. 2006 Aug; 25(34): 4647- 62.
[18] Montserrat Gómez-Zaera, Jésus Avril, Laura Gonzalez, Fernando Aguilo, Préservatif Enric, Marga Nadal, Virgine Nunes, Recherche sur les mutations/Mécanismes fondamentaux et moléculaires de la mutagenèse Volume 595, numéros 1–2, 20 mars 2006, pages 42 51.
[19] Tan DJ, Bai RK, Wong LJ. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res. 2002; 62(4): 972-976.
[20] Tan et al. Nouveaux décalages hétéroplasmiques du cadre de lecture et mutations faux-sens de l'ADN mitochondrial somatique dans le cancer de la bouche des mâcheurs de chique de bétel Gènes Chromosomes Cancer (2003).
[21] Bragoszewski P, Kupryjanczyk J, Bartnik E, Rachinger A, Ostrowski J. Limited clinical relevance of mitochondrial DNA mutation and gene expression analyses in ovarian cancer. BMC Cancer. 2008 Dec 1; 8(1): 292.
[22] Chen JZ, Gokden N, Greene GF, Mukunyadzi P, Kadlubar FF. Extensive somatic mitochondrial mutations in primary prostate cancer using laser capture microdissection. Cancer Research. 2002 Nov 15; 62(22): 6470-6474.
[23] Doupa D. Benign Breast Tumors among Senegalese Women: Diversity and Genetic Evolution of D-Loop. Open Access Library Journal. 2015; 2(08): 1.
[24] M. Kimura. The Neutral Theory of Molecular Evolution. Cambridge University Press, Cambridge, UK, 1983.
[25] Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23–28.
[26] M. Kimura. Evolutionary rate at the molecular level. Nature, 217: 624–26, 1968.
Cite This Article
  • APA Style

    Fall, H., Mbaye, F., Sembene, M. (2024). Impact of Mutations in the D-loop Region in Ovarian Cancer in Senegalese Women. International Journal of Genetics and Genomics, 12(4), 127-135. https://doi.org/10.11648/j.ijgg.20241204.18

    Copy | Download

    ACS Style

    Fall, H.; Mbaye, F.; Sembene, M. Impact of Mutations in the D-loop Region in Ovarian Cancer in Senegalese Women. Int. J. Genet. Genomics 2024, 12(4), 127-135. doi: 10.11648/j.ijgg.20241204.18

    Copy | Download

    AMA Style

    Fall H, Mbaye F, Sembene M. Impact of Mutations in the D-loop Region in Ovarian Cancer in Senegalese Women. Int J Genet Genomics. 2024;12(4):127-135. doi: 10.11648/j.ijgg.20241204.18

    Copy | Download

  • @article{10.11648/j.ijgg.20241204.18,
      author = {Habib Fall and Fatimata Mbaye and Mbacké Sembene},
      title = {Impact of Mutations in the D-loop Region in Ovarian Cancer in Senegalese Women
    },
      journal = {International Journal of Genetics and Genomics},
      volume = {12},
      number = {4},
      pages = {127-135},
      doi = {10.11648/j.ijgg.20241204.18},
      url = {https://doi.org/10.11648/j.ijgg.20241204.18},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijgg.20241204.18},
      abstract = {In Senegal, ovarian cancer is the 3rd most common cancer in women with an incidence of 5.0/100,000 women. Thirty-five cancerous tissues, twenty-seven healthy tissues were included in this study. Due to the anatomical position of the ovary, the removal of a sample of suspicious tissue from each patient involves surgery through laparotomy or laparoscopy after obtaining consent. DNA extraction, polymerase chain reaction (PCR) and sequencing were performed to obtain sequences. BioEdit version 7.0.5.3 2005, Harlequin version 3.0, DnaSP version 5.10.01, MEGA 6 were used to perform the analyses. The results show a higher percentage of transition in cancerous tissues (91.45) than in healthy tissues (75.19) in contrast to transversions which are greater in healthy tissues (24.84) than in cancerous tissues (8.54), and the mutation rate (R) is also higher in cancerous tissues (10.712) than in healthy tissues (3.079). Analysis of the polymorphism revealed high values of haplotypic diversity in both cancerous tissues (0.662±0.085) and healthy tissues (0.997±0.011), and low nucleotide diversity values in both tissues (cancerous tissues=0.00922±0.00175; healthy tissues=0.01539±0.00175), these results show us that the genetic evolution of mutations in ovarian cancer has a strong polymorphism. It was also found that the value of the genetic distance between healthy tissues (0.016) was higher than that observed between cancerous tissues (0.009). The genetic distance between healthy and cancerous tissues is 0.015 closer than that observed between healthy tissues. The value of genetic differentiation between healthy and cancerous tissues is significant; this demonstrates a much faster proliferation of cancer cells. The objective of this study is, on the one hand, to better understand the target population by clearly identifying demographic parameters and on the other hand, to evaluate the involvement of somatic mutations and mitochondrial DNA gene expression in the occurrence of ovarian cancer in women in Senegal. The specific objectives are to search for mutations of interest by sequencing mtDNA genes with quasi-maternal inheritance and the impact of these mutations in the D-loop region in healthy and diseased tissues in the patient, but also to learn about the diversity, differentiation and genetic evolution of ovarian cancer in Senegalese women.
    },
     year = {2024}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Impact of Mutations in the D-loop Region in Ovarian Cancer in Senegalese Women
    
    AU  - Habib Fall
    AU  - Fatimata Mbaye
    AU  - Mbacké Sembene
    Y1  - 2024/11/29
    PY  - 2024
    N1  - https://doi.org/10.11648/j.ijgg.20241204.18
    DO  - 10.11648/j.ijgg.20241204.18
    T2  - International Journal of Genetics and Genomics
    JF  - International Journal of Genetics and Genomics
    JO  - International Journal of Genetics and Genomics
    SP  - 127
    EP  - 135
    PB  - Science Publishing Group
    SN  - 2376-7359
    UR  - https://doi.org/10.11648/j.ijgg.20241204.18
    AB  - In Senegal, ovarian cancer is the 3rd most common cancer in women with an incidence of 5.0/100,000 women. Thirty-five cancerous tissues, twenty-seven healthy tissues were included in this study. Due to the anatomical position of the ovary, the removal of a sample of suspicious tissue from each patient involves surgery through laparotomy or laparoscopy after obtaining consent. DNA extraction, polymerase chain reaction (PCR) and sequencing were performed to obtain sequences. BioEdit version 7.0.5.3 2005, Harlequin version 3.0, DnaSP version 5.10.01, MEGA 6 were used to perform the analyses. The results show a higher percentage of transition in cancerous tissues (91.45) than in healthy tissues (75.19) in contrast to transversions which are greater in healthy tissues (24.84) than in cancerous tissues (8.54), and the mutation rate (R) is also higher in cancerous tissues (10.712) than in healthy tissues (3.079). Analysis of the polymorphism revealed high values of haplotypic diversity in both cancerous tissues (0.662±0.085) and healthy tissues (0.997±0.011), and low nucleotide diversity values in both tissues (cancerous tissues=0.00922±0.00175; healthy tissues=0.01539±0.00175), these results show us that the genetic evolution of mutations in ovarian cancer has a strong polymorphism. It was also found that the value of the genetic distance between healthy tissues (0.016) was higher than that observed between cancerous tissues (0.009). The genetic distance between healthy and cancerous tissues is 0.015 closer than that observed between healthy tissues. The value of genetic differentiation between healthy and cancerous tissues is significant; this demonstrates a much faster proliferation of cancer cells. The objective of this study is, on the one hand, to better understand the target population by clearly identifying demographic parameters and on the other hand, to evaluate the involvement of somatic mutations and mitochondrial DNA gene expression in the occurrence of ovarian cancer in women in Senegal. The specific objectives are to search for mutations of interest by sequencing mtDNA genes with quasi-maternal inheritance and the impact of these mutations in the D-loop region in healthy and diseased tissues in the patient, but also to learn about the diversity, differentiation and genetic evolution of ovarian cancer in Senegalese women.
    
    VL  - 12
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • Genomics Laboratory, Department of Animal Biology, Faculty of Science and Technology, Cheikh Anta Diop University, Dakar, Senegal

  • Genomics Laboratory, Department of Animal Biology, Faculty of Science and Technology, Cheikh Anta Diop University, Dakar, Senegal

  • Genomics Laboratory, Department of Animal Biology, Faculty of Science and Technology, Cheikh Anta Diop University, Dakar, Senegal

  • Abstract
  • Keywords
  • Document Sections

    1. 1. Introduction
    2. 2. Materials Et Methods
    3. 3. Results
    4. 4. Discussion
    5. 5. Conclusion
    Show Full Outline
  • Abbreviations
  • Conflicts of Interest
  • References
  • Cite This Article
  • Author Information